Impact of a single fecal microbiome transplantation in adult women with anorexia nervosa: an open-label feasibility pilot trial

Anorexia nervosa (AN) is a severe mental disorder characterized by restrictive eating and disturbance in the way one's body weight or shape is experienced, often accompanied by depression and anxiety. Current evidence-based treatments for AN have limited efficacy, with less than half of the patients achieving full recovery in long-term follow-up studies. Recent findings have identified gut microbiota (GM) dysbiosis as a potential contributor to AN pathology through the gut-brain axis. This open-label, non-randomized, feasibility trial (Clinicaltrials.gov Identifier: NCT05834010) evaluated the feasibility of utilizing fecal microbiota transplantation (FMT) to modify the GM and GM-associated signaling in females with AN and to examine biological effects following a single FMT procedure. Adult female participants diagnosed with AN were recruited. FMT was administered either orally via capsules or as rectal enema. Stool and blood samples were collected pre- and one week post-FMT to assess GM composition, hormonal changes, and biomarkers. Primary endpoints: Feasibility of FMT in individuals with AN and preferred route of FMT. Secondary endpoints: A single FMT treatment can alter GM composition in individuals with AN short term and relevant gut brain signaling in serum. 18/22 participants (81%) completed FMT and sampling and 19/22 participants chose oral capsules, with no serious adverse effects reported. GM analysis showed significant shifts toward donor composition 1-week post-FMT, with improved stool consistency. No significant changes were observed in psychopathology measures or appetite-related biomarkers. Oral FMT is a feasible intervention for adult women with AN, leading to changes in GM profile. Future studies should focus on placebo-controlled trials to assess the efficacy of repeated oral treatments and explore long-term effects on GM, appetite, body weight, sex hormones, disorder-specific symptoms, and overall well-being.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-01-14
DOI
https://doi.org/10.1038/s41467-026-68455-8
Primary Topic
Eating Disorders and Behaviors
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of a single fecal microbiome transplantation in adult women with anorexia nervosa: an open-label feasibility pilot trial

Hengameh Chloé Mirsepasi-Lauridsen, Farhad M. Panah, Arendt Rasmussen Morten, Nadia Micali et al.
Nature Communications
Eating Disorders and Behaviors
article

Impact of a single fecal microbiome transplantation in adult women with anorexia nervosa: an open-label feasibility pilot trial

Hengameh Chloé Mirsepasi-Lauridsen, Farhad M. Panah, Arendt Rasmussen Morten, Nadia Micali, Morten Helms, R. Støving, Magnus Sjögren, Kenneth Klingenberg Barfod, Kia Reis, Dennis Sandris Nielsen, Andreas Munk Petersen, Sina Maschek
article en

Abstract

Anorexia nervosa (AN) is a severe mental disorder characterized by restrictive eating and disturbance in the way one's body weight or shape is experienced, often accompanied by depression and anxiety. Current evidence-based treatments for AN have limited efficacy, with less than half of the patients achieving full recovery in long-term follow-up studies. Recent findings have identified gut microbiota (GM) dysbiosis as a potential contributor to AN pathology through the gut-brain axis. This open-label, non-randomized, feasibility trial (Clinicaltrials.gov Identifier: NCT05834010) evaluated the feasibility of utilizing fecal microbiota transplantation (FMT) to modify the GM and GM-associated signaling in females with AN and to examine biological effects following a single FMT procedure. Adult female participants diagnosed with AN were recruited. FMT was administered either orally via capsules or as rectal enema. Stool and blood samples were collected pre- and one week post-FMT to assess GM composition, hormonal changes, and biomarkers. Primary endpoints: Feasibility of FMT in individuals with AN and preferred route of FMT. Secondary endpoints: A single FMT treatment can alter GM composition in individuals with AN short term and relevant gut brain signaling in serum. 18/22 participants (81%) completed FMT and sampling and 19/22 participants chose oral capsules, with no serious adverse effects reported. GM analysis showed significant shifts toward donor composition 1-week post-FMT, with improved stool consistency. No significant changes were observed in psychopathology measures or appetite-related biomarkers. Oral FMT is a feasible intervention for adult women with AN, leading to changes in GM profile. Future studies should focus on placebo-controlled trials to assess the efficacy of repeated oral treatments and explore long-term effects on GM, appetite, body weight, sex hormones, disorder-specific symptoms, and overall well-being.

Nature CommunicationsVol. 17(1)
University of Copenhagen (DK), Sundsvall Municipality (SE), Great Ormond Street Hospital (GB), Odense University Hospital (DK), Hvidovre Hospital (DK), Copenhagen University Hospital (DK), Copenhagen Prospective Studies on Asthma in Childhood (DK), Center for Clinical & Basic Research (DK), Capital Region of Denmark (DK), Danish Ministry of Food, Agriculture and Fisheries (DK), University College London (GB)
Lundbeckfonden, H. Lundbeck A/S
Good health and well-being
Openalex Percentile: Top 89%
Eating Disorders and Behaviors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.